Aravive Inc Quick Ratio (ARAV) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aravive Inc   (NASDAQ: ARAV)

Aravive Inc 's Quick Ratio

ARAV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.87 a new company low.

Within Major Pharmaceutical Preparations industry 237 other companies have achieved higher Quick Ratio than Aravive Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 1231, from total ranking in the second quarter 2023 at 1680.

Explain Quick Ratio?
How much Cash & cash equivalents ARAV´s has?
What are ARAV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARAV Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -58.8 % -33.76 % -7.62 % 23.25 % 67.18 %
Y / Y Cash & cash equivalent Change -69.4 % -60.8 % -45.42 % -9.65 % -58.68 %
Quick Ratio MRQ 0.87 1.29 1.78 2.43 1.18
ARAV's Total Ranking # 1231 # 1680 # 1408 # 1186 # 1885
Seq. Current Liabilities Change -31.25 % -29.57 % -8.68 % -6.82 % 10.53 %
Seq. Cash & cash equivalent Change -53.51 % -48.89 % -33.09 % 92.46 % -40.44 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 238
Healthcare Sector # 467
Overall Market # 1231


Quick Ratio Statistics
High Average Low
42.34 14.29 0.87
(Sep 30 2014)   (Sep 30 2023)




Financial Statements
Aravive Inc 's Current Liabilities $ 10 Millions Visit ARAV's Balance sheet
Aravive Inc 's Cash & cash equivalent $ 9 Millions Visit ARAV's Balance sheet
Source of ARAV's Sales Visit ARAV's Sales by Geography


Cumulative Aravive Inc 's Quick Ratio

ARAV's Quick Ratio for the trailling 12 Months

ARAV Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -22 % 6.35 % 33.41 % 68.77 % 91.63 %
Y / Y Cash & cash equivalent TTM Growth -41.74 % -43.29 % -38.72 % -30.89 % -29.13 %
Quick Ratio TTM 1.76 1.69 1.88 2.18 2.35
Total Ranking TTM # 3825 # 1241 # 3802 # 668 # 3739
Seq. Current Liabilities TTM Growth -17.39 % -8.28 % -1.87 % 4.91 % 12.64 %
Seq. Cash & cash equivalent TTM Growth -14.25 % -17.33 % -15.39 % -2.87 % -16.53 %

Quick ratio ranking by company, industry and sector >> Back to ARAV Financial Strength Comparisons >> Go to Compare ARAV Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Aravive Inc 's average Cash & cash equivalent, this led to increase in in Aravive Inc 's Quick Ratio to 1.76, Quick Ratio remained below ARAV average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 525 other companies have achieved higher Quick Ratio than Aravive Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1241 to 3825.

Explain Quick Ratio?
How much Cash & cash equivalents ARAV´s has?
What are ARAV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 526
Healthcare Sector # 1053
Within the Market # 3825


trailing twelve months Quick Ratio Statistics
High Average Low
20.73 7.65 1.69
(Dec 31 2018)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Beone Medicines Ltd   2.40 $ 3,078.884  Millions$ 1,283.297  Millions
Apollomics Inc   2.36 $ 32.056  Millions$ 13.556  Millions
Vincerx Pharma Inc   2.35 $ 20.802  Millions$ 8.846  Millions
Madrigal Pharmaceuticals Inc   2.34 $ 232.351  Millions$ 99.152  Millions
Siga Technologies Inc  2.31 $ 71.114  Millions$ 30.745  Millions
Insmed Inc  2.30 $ 785.951  Millions$ 341.213  Millions
Bioxcel Therapeutics Inc   2.28 $ 89.961  Millions$ 39.408  Millions
Galera Therapeutics Inc   2.25 $ 28.364  Millions$ 12.630  Millions
Precigen Inc   2.24 $ 73.755  Millions$ 32.875  Millions
Hutchmed china Limited  2.20 $ 886.336  Millions$ 403.027  Millions
Iterum Therapeutics Plc  2.19 $ 35.892  Millions$ 16.396  Millions
Acurx Pharmaceuticals inc   2.19 $ 7.052  Millions$ 3.223  Millions
Curevac N v   2.19 $ 456.571  Millions$ 208.756  Millions
Seres Therapeutics Inc   2.14 $ 169.912  Millions$ 79.225  Millions
Eton Pharmaceuticals Inc   2.12 $ 22.070  Millions$ 10.393  Millions
Omeros Corporation  2.11 $ 310.310  Millions$ 147.176  Millions
Catalyst Pharmaceuticals Inc   2.09 $ 120.971  Millions$ 57.806  Millions
Hcw Biologics Inc   2.07 $ 11.221  Millions$ 5.417  Millions
Canton Strategic Holdings Inc   2.02 $ 2.689  Millions$ 1.329  Millions
Renovorx Inc   2.01 $ 3.226  Millions$ 1.605  Millions
Oculis Holding Ag  2.01 $ 45.600  Millions$ 22.710  Millions
Grace Therapeutics Inc  2.00 $ 10.611  Millions$ 5.314  Millions
Vaxxinity Inc   1.97 $ 42.519  Millions$ 21.561  Millions
Galectin Therapeutics Inc   1.94 $ 20.362  Millions$ 10.522  Millions
Cdt Equity Inc   1.88 $ 8.644  Millions$ 4.603  Millions
Adlai Nortye Ltd  1.82 $ 91.492  Millions$ 50.317  Millions
Geovax Labs Inc   1.79 $ 12.687  Millions$ 7.082  Millions
Alkermes Plc   1.77 $ 889.150  Millions$ 503.107  Millions
Tempest Therapeutics Inc   1.76 $ 11.118  Millions$ 6.305  Millions
Nucana Plc  1.76 $ 28.478  Millions$ 16.153  Millions

Date modified: 2026-09-26T07:02:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.